301166 优宁维
已收盘 05-29 15:00:00
资讯
新帖
简况
优宁维（301166）披露关于回购公司股份方案的公告，5月27日股价下跌2.02%
证券之星 · 05-27 22:48
优宁维（301166）披露关于回购公司股份方案的公告，5月27日股价下跌2.02%
优宁维(301166.SZ)拟推第一期员工持股计划
智通财经 · 05-27 19:26
优宁维(301166.SZ)拟推第一期员工持股计划
优宁维最新公告：拟1500万元至3000万元回购公司股份
证券之星 · 05-27 19:20
优宁维最新公告：拟1500万元至3000万元回购公司股份
优宁维（301166）披露回购股份注销完成暨股份变动公告，5月25日股价下跌0.96%
证券之星 · 05-25
优宁维（301166）披露回购股份注销完成暨股份变动公告，5月25日股价下跌0.96%
优宁维：公司主要面向高等院校、科研院所、医院和生物医药企业等科研端
证券之星 · 05-15
优宁维：公司主要面向高等院校、科研院所、医院和生物医药企业等科研端
优宁维（301166）披露回购股份实施完成暨股份变动公告，5月13日股价上涨0.03%
证券之星 · 05-13
优宁维（301166）披露回购股份实施完成暨股份变动公告，5月13日股价上涨0.03%
股市必读：优宁维（301166）5月8日披露最新机构调研信息
证券之星 · 05-11
股市必读：优宁维（301166）5月8日披露最新机构调研信息
每周股票复盘：优宁维（301166）股东户数增17.43%
证券之星 · 05-03
每周股票复盘：优宁维（301166）股东户数增17.43%
优宁维（301166）2026年一季报简析：增收不增利
证券之星 · 04-29
优宁维（301166）2026年一季报简析：增收不增利
优宁维（301166）披露2025年度募集资金存放与使用情况，4月28日股价下跌1.75%
证券之星 · 04-28
优宁维（301166）披露2025年度募集资金存放与使用情况，4月28日股价下跌1.75%
图解优宁维年报：第四季度单季净利润同比下降100.23%
证券之星 · 04-28
图解优宁维年报：第四季度单季净利润同比下降100.23%
优宁维：公司目前暂无重组事项
证券之星 · 04-22
优宁维：公司目前暂无重组事项
优宁维：公司全资子公司上海乐备实生物技术有限公司作为向客户提供实验室检测服务的实施主体
证券之星 · 04-14
优宁维：公司全资子公司上海乐备实生物技术有限公司作为向客户提供实验室检测服务的实施主体
股市必读：优宁维（301166）4月9日董秘有最新回复
证券之星 · 04-10
股市必读：优宁维（301166）4月9日董秘有最新回复
优宁维：与礼来（中国）研发有限公司、阿斯利康投资（中国）有限公司有过业务合作
证券之星 · 04-09
优宁维：与礼来（中国）研发有限公司、阿斯利康投资（中国）有限公司有过业务合作
优宁维（301166）披露回购公司股份进展公告，4月3日股价下跌3.83%
证券之星 · 04-03
优宁维（301166）披露回购公司股份进展公告，4月3日股价下跌3.83%
优宁维：公司自主研发主要集中于抗体及抗体相关领域
证券之星 · 04-02
优宁维：公司自主研发主要集中于抗体及抗体相关领域
优宁维：围绕两个极致战略，提升渠道和产品研发能力
证券之星 · 03-27
优宁维：围绕两个极致战略，提升渠道和产品研发能力
优宁维跌5.5% 2021年上市即巅峰超募13亿
中金财经 · 03-20
优宁维跌5.5% 2021年上市即巅峰超募13亿
免疫治疗概念震荡走强 开能健康、优宁维涨超11%
人民财讯 · 03-18
免疫治疗概念震荡走强 开能健康、优宁维涨超11%
加载更多
公司概况
公司名称：
上海优宁维生物科技股份有限公司
所属行业：
批发业
上市日期：
2021-12-28
主营业务：
上海优宁维生物科技股份有限公司的主营业务是提供以抗体为核心的生命科学试剂及相关仪器、耗材和综合技术服务。公司的主要产品是生命科学试剂、生命科学仪器及耗材。
发行价格：
86.06
{"stockData":{"symbol":"301166","market":"SZ","secType":"STK","nameCN":"优宁维","latestPrice":28.25,"timestamp":1780038234000,"preClose":28.7,"halted":0,"volume":1178700,"delay":0,"changeRate":-0.0157,"floatShares":56420500,"shares":86168500,"eps":-0.2929,"marketStatus":"已收盘","change":-0.45,"latestTime":"05-29 15:00:00","open":28.86,"high":28.99,"low":28.2,"amount":33541200,"amplitude":0.0275,"askPrice":28.28,"askSize":2,"bidPrice":28.25,"bidSize":34,"shortable":0,"etf":0,"ttmEps":-0.2929,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780277400000},"marketStatusCode":5,"adr":0,"adjPreClose":28.7,"symbolType":"stock","openAndCloseTimeList":[[1780018200000,1780025400000],[1780030800000,1780038000000]],"highLimit":31.57,"lowLimit":25.83,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":86168468,"isCdr":false,"pbRate":1.24,"roa":"--","roe":"--","epsLYR":-0.26,"committee":0.454545,"marketValue":2434000000,"turnoverRate":0.0209,"status":1,"floatMarketCap":1594000000},"requestUrl":"/m/hq/s/301166","defaultTab":"news","newsList":[{"id":"2638890286","title":"优宁维（301166）披露关于回购公司股份方案的公告，5月27日股价下跌2.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638890286","media":"证券之星","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638890286?lang=zh_cn&edition=full","pubTime":"2026-05-27 22:48","pubTimestamp":1779893297,"startTime":"0","endTime":"0","summary":"截至2026年5月27日收盘，优宁维报收于28.69元，较前一交易日下跌2.02%，最新总市值为24.72亿元。近日，优宁维发布《关于回购公司股份方案的公告》。公告显示，公司拟以集中竞价交易方式回购公司股份，回购股份将用于股权激励或员工持股计划。预计回购股份数量为33.33万股至66.67万股，占公司目前总股本的0.39%至0.77%。公司董事、高级管理人员、控股股东等在回购前六个月内无买卖股票行为，且截至公告日无明确减持计划。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700046437.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638603502","title":"优宁维(301166.SZ)拟推第一期员工持股计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2638603502","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638603502?lang=zh_cn&edition=full","pubTime":"2026-05-27 19:26","pubTimestamp":1779881181,"startTime":"0","endTime":"0","summary":"智通财经APP讯，优宁维(301166.SZ)发布第一期员工持股计划(草案)，持股计划股票来源为公司回购专用账户回购的优宁维A股普通股股票，股票总量不超过92.76万股，占员工持股计划草案公告日公司股本总额的1.08%。持股计划购买回购股份的价格为15.89元/股。持股计划的存续期为72个月，所获标的股票分三期解锁，锁定期分别为12个月、24个月、36个月，均自本员工持股计划草案经公司股东会审议通过且公司公告最后一笔标的股票过户至本员工持股计划名下之日起计算，每期解锁比例分别为30%、40%、30%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446757.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301166","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638502391","title":"优宁维最新公告：拟1500万元至3000万元回购公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2638502391","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638502391?lang=zh_cn&edition=full","pubTime":"2026-05-27 19:20","pubTimestamp":1779880829,"startTime":"0","endTime":"0","summary":"优宁维(301166.SZ)公告称，公司拟以集中竞价交易方式回购公司股份，回购资金总额不低于1500万元(含)且不超过3000万元(含)，回购价格不超过45元/股。回购的股份将用于股权激励或员工持股计划。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700040249.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638582532","title":"优宁维（301166）披露回购股份注销完成暨股份变动公告，5月25日股价下跌0.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638582532","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638582532?lang=zh_cn&edition=full","pubTime":"2026-05-25 18:32","pubTimestamp":1779705135,"startTime":"0","endTime":"0","summary":"截至2026年5月25日收盘，优宁维报收于29.94元，较前一交易日下跌0.96%，最新总市值为25.8亿元。该股当日开盘30.2元，最高30.82元，最低29.53元，成交额达4267.73万元，换手率为2.52%。公告显示，上海优宁维生物科技股份有限公司本次注销回购股份498,200股，占注销前总股本的0.57%。注销完成后，公司总股本由86,666,668股变更为86,168,468股。公司已于2026年5月21日在中国证券登记结算有限责任公司深圳分公司办理完成注销手续。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500026531.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635277918","title":"优宁维：公司主要面向高等院校、科研院所、医院和生物医药企业等科研端","url":"https://stock-news.laohu8.com/highlight/detail?id=2635277918","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635277918?lang=zh_cn&edition=full","pubTime":"2026-05-15 11:33","pubTimestamp":1778816000,"startTime":"0","endTime":"0","summary":"证券之星消息，优宁维(301166)05月14日在投资者关系平台上答复投资者关心的问题。投资者提问：冷总，公司在防病毒领域有没有设计相关产品？优宁维回复：投资者您好，公司主要面向高等院校、科研院所、医院和生物医药企业等科研端，提供生命科学试剂、设备、耗材、综合技术服务等产品和服务，产品覆盖基因、蛋白、细胞、组织及动物等不同水平的研究对象，助力生命科学的发展和创新。谢谢以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500018570.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161726","BK0250","301166","399441"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635573596","title":"优宁维（301166）披露回购股份实施完成暨股份变动公告，5月13日股价上涨0.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635573596","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635573596?lang=zh_cn&edition=full","pubTime":"2026-05-13 22:47","pubTimestamp":1778683635,"startTime":"0","endTime":"0","summary":"截至2026年5月13日收盘，优宁维报收于31.73元，较前一交易日上涨0.03%，最新总市值为27.5亿元。公司于2026年5月13日发布《关于回购股份实施完成暨股份变动的公告》。公告显示，上海优宁维生物科技股份有限公司于2025年4月10日审议通过回购股份方案，拟使用1500万元至3000万元自有资金以集中竞价方式回购股份，用于注销并减少注册资本，回购价格不超过44元/股。回购股份将全部注销。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300045965.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634542601","title":"股市必读：优宁维（301166）5月8日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2634542601","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634542601?lang=zh_cn&edition=full","pubTime":"2026-05-11 03:36","pubTimestamp":1778441772,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，优宁维报收于32.18元，上涨1.61%，换手率2.84%，成交量1.61万手，成交额5156.33万元。来自机构调研要点：自主品牌收入同比增长超30%，带动整体毛利率同比提升。②2025 年全年营收 10.84 亿元，但净利润亏损 2,295 万元；2026 年Q1 营收 2.59 亿元，净利润继续亏损 850 万元。详细介绍可查阅公司于 2026年 4月 28日披露的 2025年年度报告“第三节管理层讨论与分析”之“三、核心竞争力分析”中的内容。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100001662.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632456670","title":"每周股票复盘：优宁维（301166）股东户数增17.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632456670","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632456670?lang=zh_cn&edition=full","pubTime":"2026-05-03 07:16","pubTimestamp":1777763770,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，优宁维报收于31.02元，较上周的30.65元上涨1.21%。本周，优宁维4月30日盘中最高价报31.14元。股本股东变化股东户数变动截至2026年3月31日，优宁维股东户数为1.16万户，较2025年12月31日增加1726.0户，增幅达17.43%。2025年年度审计报告优宁维2025年度合并营业收入为1,083,706,364.04元，归属于母公司净利润为-22,948,743.49元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300001752.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631557141","title":"优宁维（301166）2026年一季报简析：增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2631557141","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631557141?lang=zh_cn&edition=full","pubTime":"2026-04-29 12:31","pubTimestamp":1777437089,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期优宁维发布2026年一季报。根据财报显示，优宁维增收不增利。其中，毛利率20.31%，同比增12.11%，净利率-3.28%，同比减14.18%，销售费用、管理费用、财务费用总计4608.4万元，三费占营收比17.77%，同比减0.0%，每股净资产23.0元，同比减3.01%，每股经营性现金流-1.39元，同比减421.96%，每股收益-0.1元，同比减42.86%证券之星价投圈财报分析工具显示：业务评价：去年的净利率为-2.12%，算上全部成本后，公司产品或服务的附加值不高。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900041038.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630058517","title":"优宁维（301166）披露2025年度募集资金存放与使用情况，4月28日股价下跌1.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630058517","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630058517?lang=zh_cn&edition=full","pubTime":"2026-04-28 22:38","pubTimestamp":1777387091,"startTime":"0","endTime":"0","summary":"截至2026年4月28日收盘，优宁维报收于30.36元，较前一交易日下跌1.75%，最新总市值为26.31亿元。该股当日开盘30.69元，最高31.12元，最低30.14元，成交额达5010.09万元，换手率为2.87%。近日，优宁维发布《2025年度募集资金存放与使用情况专项报告》。公告显示，截至2025年12月31日，公司累计使用募集资金1,602,266,995.61元，募集资金专户余额为8,460,672.92元。本年度投入募集资金209,981,338.80元，主要用于多个募投项目。募集资金使用符合监管规定，未发现管理违规情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800065976.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630316095","title":"图解优宁维年报：第四季度单季净利润同比下降100.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630316095","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630316095?lang=zh_cn&edition=full","pubTime":"2026-04-28 01:00","pubTimestamp":1777309259,"startTime":"0","endTime":"0","summary":"证券之星消息，优宁维2025年年报显示，当年度公司主营收入10.84亿元，同比下降3.05%；归母净利润-2294.87万元，同比下降326.12%；扣非净利润-4321.38万元，同比下降185.99%；其中2025年第四季度，公司单季度主营收入3.08亿元，同比上升6.07%；单季度归母净利润-786.92万元，同比下降100.23%；单季度扣非净利润-1293.94万元，同比下降16.64%；负债率12.88%，投资收益950.86万元，财务费用-150.29万元，毛利率18.79%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800002796.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629062975","title":"优宁维：公司目前暂无重组事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2629062975","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629062975?lang=zh_cn&edition=full","pubTime":"2026-04-22 08:51","pubTimestamp":1776819074,"startTime":"0","endTime":"0","summary":"证券之星消息，优宁维(301166)04月21日在投资者关系平台上答复投资者关心的问题。投资者提问：冷总，公司重组证监会批准了没？优宁维回复：投资者您好。公司目前暂无重组事项，谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200016094.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627467928","title":"优宁维：公司全资子公司上海乐备实生物技术有限公司作为向客户提供实验室检测服务的实施主体","url":"https://stock-news.laohu8.com/highlight/detail?id=2627467928","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627467928?lang=zh_cn&edition=full","pubTime":"2026-04-14 08:58","pubTimestamp":1776128289,"startTime":"0","endTime":"0","summary":"证券之星消息，优宁维(301166)04月13日在投资者关系平台上答复投资者关心的问题。投资者提问：冷总，您好公司有没有CRO业务？优宁维回复：投资者您好，公司全资子公司上海乐备实生物技术有限公司作为向客户提供实验室检测服务的实施主体，主要为客户提供单/多因子相关检测分析、多色流式检测以及多色组化检测等服务。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041400006327.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626131020","title":"股市必读：优宁维（301166）4月9日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2626131020","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626131020?lang=zh_cn&edition=full","pubTime":"2026-04-10 00:53","pubTimestamp":1775753623,"startTime":"0","endTime":"0","summary":"截至2026年4月9日收盘，优宁维报收于30.5元，下跌2.93%，换手率2.39%，成交量1.36万手，成交额4176.06万元。董秘最新回复投资者： 冷总，您好公司有没有和礼来阿斯利康合作？公司与礼来（中国）研发有限公司、阿斯利康投资（中国）有限公司有过业务合作，双方交易规模较小，对公司业绩不构成重大影响。交易信息汇总资金流向4月9日主力资金净流出194.17万元；游资资金净流入200.5万元；散户资金净流出6.34万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041000001863.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626904033","title":"优宁维：与礼来（中国）研发有限公司、阿斯利康投资（中国）有限公司有过业务合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2626904033","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626904033?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:00","pubTimestamp":1775721624,"startTime":"0","endTime":"0","summary":"证券之星消息，优宁维(301166)04月09日在投资者关系平台上答复投资者关心的问题。投资者提问：冷总，您好公司有没有和礼来阿斯利康合作？优宁维回复：投资者您好，公司作为生命科学一站式服务商平台，可提供生命科学所涉及的生物试剂及相关仪器、耗材和综合技术服务。公司与礼来（中国）研发有限公司、阿斯利康投资（中国）有限公司有过业务合作，双方交易规模较小，对公司业绩不构成重大影响。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040900023353.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624654919","title":"优宁维（301166）披露回购公司股份进展公告，4月3日股价下跌3.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624654919","media":"证券之星","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624654919?lang=zh_cn&edition=full","pubTime":"2026-04-03 18:49","pubTimestamp":1775213351,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，优宁维报收于29.86元，较前一交易日下跌3.83%，最新总市值为25.88亿元。该股当日开盘31.04元，最高31.16元，最低29.86元，成交额达6287.25万元，换手率为3.65%。近日，优宁维发布《关于回购公司股份的进展公告》。回购价格上限已由44元/股调整为43.77元/股。本次回购符合相关法律法规及公司回购方案规定。公司后续将在回购期限内继续实施回购计划，并履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300036029.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624579927","title":"优宁维：公司自主研发主要集中于抗体及抗体相关领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2624579927","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624579927?lang=zh_cn&edition=full","pubTime":"2026-04-02 15:51","pubTimestamp":1775116269,"startTime":"0","endTime":"0","summary":"证券之星消息，优宁维(301166)04月01日在投资者关系平台上答复投资者关心的问题。投资者提问：冷总，公司到底有没有在研发创新药，股权转让并购重组到哪一步了？优宁维回复：投资者您好，公司自主研发主要集中于抗体及抗体相关领域，目前公司主要围绕抗体上下游应用领域寻找相关标的企业，以实现与现有业务的协同发展，并通过参与投资的股权投资基金，投向覆盖医疗健康等领域。投资者可关注公司后续披露的公告及相关基金的投资进展。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200023456.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301166","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622982177","title":"优宁维：围绕两个极致战略，提升渠道和产品研发能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2622982177","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622982177?lang=zh_cn&edition=full","pubTime":"2026-03-27 20:51","pubTimestamp":1774615871,"startTime":"0","endTime":"0","summary":"证券之星消息，优宁维03月26日在投资者关系平台上答复投资者关心的问题。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700046142.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620873067","title":"优宁维跌5.5% 2021年上市即巅峰超募13亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2620873067","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620873067?lang=zh_cn&edition=full","pubTime":"2026-03-20 18:23","pubTimestamp":1774002195,"startTime":"0","endTime":"0","summary":"中国经济网北京3月20日讯 优宁维 今日收报32.11元，跌幅5.50%。 2021年12月28日，优宁维在深交所创业板上市，公开发行股票2166.67万股，发行价格为86.06元/股。 优宁维首次公开发行股票募集资金总额为18.65亿元，扣除发行费用后，募集资金净额为15.96亿元。优宁维最终募集资金净额比原计划多13.12亿元。 优宁维首次公开发行股票的发行费用合计2.69亿元，国联民生获得承销及保荐费用2.48亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260320/32085393.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0250","301166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620283483","title":"免疫治疗概念震荡走强 开能健康、优宁维涨超11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620283483","media":"人民财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620283483?lang=zh_cn&edition=full","pubTime":"2026-03-18 10:44","pubTimestamp":1773801872,"startTime":"0","endTime":"0","summary":"人民财讯3月18日电，免疫治疗概念震荡走强，开能健康、优宁维涨超11%，中源协和、荣昌生物、济民健康、益诺思等涨幅居前。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603183675702952.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0020","BK0224","BK0042","BK0135","300272","BK0046","BK0250","BK0150","301166"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1780070637031,"stockEarnings":[{"period":"1week","weight":-0.0369},{"period":"1month","weight":-0.0547},{"period":"3month","weight":-0.1405},{"period":"6month","weight":-0.1123},{"period":"1year","weight":-0.0024},{"period":"ytd","weight":-0.033}],"compareEarnings":[{"period":"1week","weight":0.0052},{"period":"1month","weight":0.0049},{"period":"3month","weight":-0.0154},{"period":"6month","weight":0.054},{"period":"1year","weight":0.2272},{"period":"ytd","weight":0.0327}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海优宁维生物科技股份有限公司","boardCode":"AI0051","boardName":"批发业","stockholders":"11627人(较上一季度增加17.43%)","perCapita":"4852股","listingDate":"2021-12-28","address":"上海市杨浦区控江路1690号1505室","registeredCapital":"8616万元","survey":" 上海优宁维生物科技股份有限公司的主营业务是提供以抗体为核心的生命科学试剂及相关仪器、耗材和综合技术服务。公司的主要产品是生命科学试剂、生命科学仪器及耗材。","listedPrice":86.06},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"优宁维(301166)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供优宁维(301166)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"优宁维,301166,优宁维股票,优宁维股票老虎,优宁维股票老虎国际,优宁维行情,优宁维股票行情,优宁维股价,优宁维股市,优宁维股票价格,优宁维股票交易,优宁维股票购买,优宁维股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"优宁维(301166)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供优宁维(301166)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}